Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by WalterTheDawgon May 10, 2022 11:05am
166 Views
Post# 34670401

RE:RE:RE:RE:TS buys more

RE:RE:RE:RE:TS buys moreSo you would do well to read all their news releases for the last year or so on their website but essentially they have a stem cell treatment that they have proven with a bunch of small scale trials to save peoples limbs in the case of reduced blood flow to extremeties called CLI also this treatment has been shown to effectively regenerate damaged heart tissues. So this bigger trial for CLI has been ongoing for years but because of a string of sh1t CEOs and a licensee who was essentially trying to steal the IP, it has taken until now to sort out all their legal problems. Now we finally have the data and once they analyze it, and it shows what we all suspect it will (great efficacy for a currently uncurrable condition) then the stock will naturally rise to reflect the treatments much larger chance of becoming a lucrative medicine. Today is a good day but the market needs further convincing so i am waiting for the phase 2 results which shouldnt be far off. Good luck man!
<< Previous
Bullboard Posts
Next >>